In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. - "Our study uncovered the crucial purpose in the KLF16/MYC regulatory https://elizabethq988doa1.fliplife-wiki.com/user